Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 241-250 of 411 for multiple

Edit search filters
  1. A Study Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Locally Advanced Unresectable Or Metastatic Gastric Or Gastroesophageal Junction Cancer (G/GEJ) (Morpheus-Gastric Cancer)

    Scottsdale/Phoenix, AZ, Rochester, MN

  2. IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy

    Rochester, MN

  3. A Study Of The Safety And Tolerability Of JNJ-55920839, Either As A Single Ascending Dose In Healthy Individuals Or As Multiple Doses For Patients Who Have Mild To Moderate Systemic Lupus Erythematosus

    Rochester, MN

  4. A Study Of Belantamab Mafodotin Administered In Combination With Lenalidomide And Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, And Dexamethasone (DRd) In Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible For Autologous Stem Cell Transplantation (TI-NDMM)

    Scottsdale/Phoenix, AZ

  5. Understanding The Challenges, Behavioral Patterns, And Preferences Towards Participation In Clinical Trials In Minority Patient Populations

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  6. A Study To Assess A Change In Disease Activity And Adverse Events Of Intravenous Etentamig And Daratumumab (Etentamig+D) Compared To Daratumumab, Lenalidomide, And Dexamethasone (DRd) In Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible For Transplant

    Scottsdale/Phoenix, AZ, Rochester, MN

  7. A Study To Assess The MEK Inhibitor Mirdametinib (PD-0325901) In Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

    Scottsdale/Phoenix, AZ, Rochester, MN

  8. A Study Of Binimetinib In Children And Adults With NF1 Plexiform Neurofibromas

    Rochester, MN

  9. An Efficacy And Safety Study Of Daratumumab In Patients With Multiple Myeloma Who Have Received At Least 3 Prior Lines Of Therapy (Including A Proteasome Inhibitor [PI] And Immunomodulatory Drug [IMiD]) Or Are Double Refractory To A PI And An IMiD

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  10. A Study To Evaluate Exercise For Cancer Patients At Risk Of Falling

    Rochester, MN

.

Mayo Clinic Footer